title: Agenus‘ genital herpes vaccine significantly reduces viral burden in Phase 2.
authors.forename: Eva M
authors.initials: EM
authors.lastname: Riedmann
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D055815:Young Adult; D017322:Clinical Trials, Phase II as Topic; D006558:Herpes Genitalis / Q000276:immunology / Q000517:prevention & control / Q000821:virology; D018258:Herpesvirus 2, Human / Q000302:isolation & purification; D022283:Herpesvirus Vaccines / Q000008:administration & dosage / Q000276:immunology; D019562:Viral Load
chemical_list: D022283:Herpesvirus Vaccines